Propel Bio Management, LLC — 13F Holdings & Portfolio

CIK 1969764 · latest 13F-HR filed 2026-11-13

Propel Bio Management, LLC manages $188.6M in 13F-reported U.S. long-equity assets across 30 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are PAGP (17.47%), QUIT (16.57%), DCTH (5.12%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 5 new positions and exited 4; 7 existing positions rose in reported value and 18 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$188.6M

Long-equity book

Holdings
30

Distinct positions

Period
2026-09-30

Filed 2026-11-13

Q/Q Activity
+5 / −4 / ↑7 / ↓18

vs 2026-06-30

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q3 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q2 26 → Q3 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

5 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 68.3%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 23, 2026.

Assets Under Management
$247.5M
Discretionary
$247.5M
Employees
7
Accounts
5
Address
11620 WILSHIRE BLVD
SUITE 350
LOS ANGELES, CA 90025
Phone
(206) 602-9246
Name Title / Status Ownership Type
HARDING, JAMES, FRANCIS ControlCHIEF COMPLIANCE OFFICER
since Mar 2026
Less than 5%Individual
KAWAS, LEEN ControlMANAGING GENERAL PARTNER
since Jan 2022
75% or moreIndividual
Ownership & leadership changes · 2 filings with changes since Oct 17, 2022

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Mar 23, 2026 filing
  • No longer listedHua, Xue · CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Mar 2024
  • Listed againHARDING, JAMES, FRANCIS · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
Mar 25, 2024 filing
  • No longer listedHARDING, JAMES, FRANCIS · CHIEF COMPLIANCE OFFICER · Less than 5% · listed since Sep 2022
  • AddedHua, Xue · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
Oct 17, 2022 filing (earliest on record)
  • ListedHARDING, JAMES, FRANCIS · CHIEF COMPLIANCE OFFICER · Less than 5%
  • ListedKAWAS, LEEN · MANAGING GENERAL PARTNER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Propel Bio Management, LLC Holdings (2026-09-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 PLAINS GP HOLDINGS LP PAGP 72651A207 $33.0M 17.47% 1,272,360 SH
2 ACHIEVE LIFE SCIENCES INC QUIT 004468500 $31.3M 16.57% 3,864,148 SH
3 DELCATH SYSTEMS INC DCTH 24661P807 $9.7M 5.12% 604,664 SH
4 COLLEGIUM PHARMACEUTICAL COLL 19459J104 $9.0M 4.75% 410,175 SH
5 CORCEPT THERAPEUTICS INC CORT 218352102 $8.7M 4.60% 75,274 SH
6 AQUESTIVE THERAPEUTICS INC AQST 03843E104 $8.6M 4.56% 278,723 SH
7 MILESTONE PHARMACEUTICALS MIST 59935V107 $8.2M 4.34% 9,449,727 SH
8 PHATHOM PHARMACEUTICALS I PHAT 71722W107 $8.1M 4.28% 1,105,913 SH
9 COMPASS PATHWAYS PLC CMPS 20451W101 $6.8M 3.62% 549,186 SH
10 ORCHESTRA BIOMED HOLDINGS OBIO 68572M106 $5.6M 2.96% 896,701 SH
11 MAZE THERAPEUTICS INC MAZE 578784100 $5.2M 2.77% 191,998 SH
12 ABEONA THERAPEUTICS INC ABEO 00289Y206 $5.0M 2.66% 956,007 SH
13 ARTIVA BIOTHERAPEUTICS IN ARTV 04317A107 $5.0M 2.63% 696,436 SH
14 KYVERNA THERAPEUTICS INC KYTX 501976104 $4.8M 2.53% 700,595 SH
15 INVENTIVA SA - ADR IVA 46124U107 $4.2M 2.22% 1,133,954 SH
16 CABALETTA BIO INC CABA 12674W109 $3.9M 2.09% 2,049,471 SH
17 SAB BIOTHERAPEUTICS INC SABS 78397T202 $3.8M 2.00% 1,187,422 SH
18 PROKIDNEY CORP PROK 74291D104 $3.3M 1.77% 2,009,733 SH
19 CORVUS PHARMACEUTICALS INC CRVS 221015100 $3.0M 1.61% 264,310 SH
20 PALISADE BIO INC PALI 696389402 $3.0M 1.59% 2,224,189 SH
21 OCULAR THERAPEUTIX INC OCUL 67576A100 $2.7M 1.46% 357,966 SH
22 SCYNEXIS INC SCYX 811292309 $2.7M 1.42% 541,474 SH
23 4D MOLECULAR THERAPEUTICS IN FDMT 35104E100 $2.6M 1.36% 179,154 SH
24 OVID THERAPEUTICS INC OVID 690469101 $2.5M 1.34% 1,018,721 SH
25 IMMUNIC INC IMUX 4525EP200 $2.2M 1.17% 236,734 SH
26 UPSTREAM BIO INC UPB 91678A107 $1.8M 0.94% 335,389 SH
27 OPUS GENETICS INC IRD 67577R102 $1.3M 0.69% 270,036 SH
28 CELLDEX THERAPEUTICS INC CLDX 15117B202 $1.2M 0.65% 37,539 SH
29 SPYGLASS PHARMA INC SGP 85220G109 $1.1M 0.57% 41,418 SH
30 LEONABIO INC LONA 04746L203 $532.9K 0.28% 149,279 SH
Filing History
Period Filed AUM Holdings Accession
2026-09-30 2026-11-13 $188.6M 30 0001829126-26-012373
2026-06-30 2026-08-13 $191.1M 29 0001829126-26-008753
2026-03-31 2026-05-14 $158.7M 38 0000898432-26-000369
2025-12-31 2026-02-11 $117.1M 20 0000898432-26-000087
2025-09-30 2025-11-12 $99.9M 16 0000898432-25-000886
Filer Information
Address
11620 WILSHIRE BLVD.,
SUITE 350
LOS ANGELES, CA 90025
Phone
(908) 507-9629
Filing Manager
Propel Bio Management, LLC
LOS ANGELES, CA
Signatory
Jim Harding
Chief Compliance Officer